Advertisement

Topics

Oncodesign Announces Publication of an Abstract for the 54th ASCO Annual Meeting in Chicago

14:02 EDT 18 May 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Publication of phase 1 interim results on the first radiotracer generated by Oncodesign’s Nanocyclix® technology Regulatory News: ONCODESIGN (Paris:ALONC) (ALONC – FR0011766229), a biopharmaceutical comp...

Other Sources for this Article

Oncodesign
Philippe Genne, +33 (0)3 80 78 82 60
Chairman and CEO
investisseurs@oncodesign.com
or
NewCap
Investor & Media Relations
Julien Perez / Arthur Rouillé, +33 (0)1 44 71 98 52
oncodesign@newcap.eu

NEXT ARTICLE

More From BioPortfolio on "Oncodesign Announces Publication of an Abstract for the 54th ASCO Annual Meeting in Chicago"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...